Cynata Therapeutics (CYP) H2 2026 earnings summary

Executive summary

• Revenue from ordinary activities decreased by 15.2% year-over-year to $1.79 million for the year ended 30 June 2026.

• Net loss after tax narrowed slightly to $9.09 million, down 3.2% from the prior year.

• No dividends were declared for the current or prior year.

• The company announced negative efficacy results from key Phase 2 and Phase 3 clinical trials, though no safety concerns were identified.

Financial highlights

• Cash balance at year-end was $897,418, down from $5.05 million the previous year.

• Net tangible asset per share fell to negative $0.003 from $0.018.

• Net cash outflow from operating activities was $6.74 million, an improvement from $8.72 million in the prior year.

• R&D refund received totaled $1.71 million, down from $1.89 million.

• Impairment expenses of $1.35 million were recognized due to failed clinical trials.

Outlook and guidance

• The company has limited financial resources and does not generate operating revenue to fund material development activities.

• Future strategy depends on careful resource management and access to additional funding, including capital raisings or strategic transactions.

• Directors consider there are reasonable grounds for going concern, but material uncertainty exists due to funding needs.